Suppr超能文献

细微的结构差异引发普罗帕酮类似物对两种多特异性ABC转运蛋白的抑制活性:P-糖蛋白(P-gp)和乳腺癌耐药蛋白(BCRP)。

Subtle Structural Differences Trigger Inhibitory Activity of Propafenone Analogues at the Two Polyspecific ABC Transporters: P-Glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP).

作者信息

Schwarz Theresa, Montanari Floriane, Cseke Anna, Wlcek Katrin, Visvader Lene, Palme Sarah, Chiba Peter, Kuchler Karl, Urban Ernst, Ecker Gerhard F

机构信息

Department of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna, Althanstraße 14, 1090, Vienna, Austria.

Department of Medicinal Chemistry, Medical University Vienna, Währingerstraße 10, 1090, Vienna, Austria.

出版信息

ChemMedChem. 2016 Jun 20;11(12):1380-94. doi: 10.1002/cmdc.201500592. Epub 2016 Mar 10.

Abstract

The transmembrane ABC transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) are widely recognized for their role in cancer multidrug resistance and absorption and distribution of compounds. Furthermore, they are linked to drug-drug interactions and toxicity. Nevertheless, due to their polyspecificity, a molecular understanding of the ligand-transporter interaction, which allows designing of both selective and dual inhibitors, is still in its infancy. This study comprises a combined approach of synthesis, in silico prediction, and in vitro testing to identify molecular features triggering transporter selectivity. Synthesis and testing of a series of 15 propafenone analogues with varied rigidity and basicity of substituents provide first trends for selective and dual inhibitors. Results indicate that both the flexibility of the substituent at the nitrogen atom, as well as the basicity of the nitrogen atom, trigger transporter selectivity. Furthermore, inhibitory activity of compounds at P-gp seems to be much more influenced by logP than those at BCRP. Exploiting these differences further should thus allow designing specific inhibitors for these two polyspecific ABC-transporters.

摘要

跨膜ABC转运蛋白P-糖蛋白(P-gp)和乳腺癌耐药蛋白(BCRP)因其在癌症多药耐药性以及化合物吸收和分布中的作用而广为人知。此外,它们还与药物相互作用和毒性有关。然而,由于它们的多特异性,对配体-转运蛋白相互作用的分子理解仍处于起步阶段,而这种理解有助于设计选择性和双重抑制剂。本研究采用合成、计算机预测和体外测试相结合的方法来确定触发转运蛋白选择性的分子特征。对一系列15种具有不同取代基刚性和碱性的普罗帕酮类似物进行合成和测试,为选择性和双重抑制剂提供了初步趋势。结果表明,氮原子上取代基的灵活性以及氮原子的碱性都会触发转运蛋白的选择性。此外,化合物对P-gp的抑制活性似乎比其对BCRP的抑制活性受logP的影响更大。因此,进一步利用这些差异应该能够为这两种多特异性ABC转运蛋白设计出特异性抑制剂。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b4e/4949556/e66c17cac7df/CMDC-11-1380-g001.jpg

相似文献

10
Comparative Hepatic and Intestinal Efflux Transport of Statins.
Drug Metab Dispos. 2021 Sep;49(9):750-759. doi: 10.1124/dmd.121.000430. Epub 2021 Jun 23.

引用本文的文献

1
Ligand- and Structure-based Approaches for Transmembrane Transporter Modeling.
Curr Drug Res Rev. 2024;16(2):81-93. doi: 10.2174/2589977515666230508123041.
2
Development of Simple and Accurate in Silico Ligand-Based Models for Predicting ABCG2 Inhibition.
Front Chem. 2022 May 18;10:863146. doi: 10.3389/fchem.2022.863146. eCollection 2022.
3
Recent advances in the search of BCRP- and dual P-gp/BCRP-based multidrug resistance modulators.
Cancer Drug Resist. 2019 Sep 19;2(3):710-743. doi: 10.20517/cdr.2019.31. eCollection 2019.
5
The structure of the human ABC transporter ABCG2 reveals a novel mechanism for drug extrusion.
Sci Rep. 2017 Oct 23;7(1):13767. doi: 10.1038/s41598-017-11794-w.
6
Predicting drug-induced liver injury: The importance of data curation.
Toxicology. 2017 Aug 15;389:139-145. doi: 10.1016/j.tox.2017.06.003. Epub 2017 Jun 23.
7
Predicting Drug-Induced Cholestasis with the Help of Hepatic Transporters-An in Silico Modeling Approach.
J Chem Inf Model. 2017 Mar 27;57(3):608-615. doi: 10.1021/acs.jcim.6b00518. Epub 2017 Mar 8.
8
Virtual Screening of DrugBank Reveals Two Drugs as New BCRP Inhibitors.
SLAS Discov. 2017 Jan;22(1):86-93. doi: 10.1177/1087057116657513. Epub 2016 Jul 11.

本文引用的文献

1
Integrative Modeling Strategies for Predicting Drug Toxicities at the eTOX Project.
Mol Inform. 2015 Jun;34(6-7):477-84. doi: 10.1002/minf.201400193. Epub 2015 Jun 11.
2
BCRP Inhibition: from Data Collection to Ligand-Based Modeling.
Mol Inform. 2014 May;33(5):322-31. doi: 10.1002/minf.201400012. Epub 2014 Apr 11.
3
Transporters and drug-drug interactions: important determinants of drug disposition and effects.
Pharmacol Rev. 2013 May 17;65(3):944-66. doi: 10.1124/pr.113.007518. Print 2013 Jul.
4
Enantioselective synthesis of (+)-malbrancheamide B.
J Org Chem. 2013 Mar 15;78(6):2422-9. doi: 10.1021/jo3026059. Epub 2013 Feb 8.
5
An In Silico Classification Model for Putative ABCC2 Substrates.
Mol Inform. 2012 Aug;31(8):547-553. doi: 10.1002/minf.201200049. Epub 2012 Aug 9.
7
Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein.
J Med Chem. 2012 Jan 26;55(2):966-70. doi: 10.1021/jm201404w. Epub 2012 Jan 6.
8
Synthesis and antimalarial evaluation of novel benzopyrano[4,3-b]benzopyran derivatives.
Bioorg Med Chem. 2011 Sep 1;19(17):5199-206. doi: 10.1016/j.bmc.2011.07.009. Epub 2011 Jul 23.
9
A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields.
J Med Chem. 2011 Mar 24;54(6):1740-51. doi: 10.1021/jm101421d. Epub 2011 Feb 22.
10
Aurones as modulators of ABCG2 and ABCB1: synthesis and structure-activity relationships.
ChemMedChem. 2011 Apr 4;6(4):713-24. doi: 10.1002/cmdc.201000520. Epub 2011 Feb 7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验